MREO Key Statistics, Chart & Performance
The current stock price of MREO is 0.534 USD. In the past month the price decreased by -76.76%. In the past year, price decreased by -81.71%.
MREO Technical Analysis
MREO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MREO. The financial health of MREO is average, but there are quite some concerns on its profitability.
MREO Financial Highlights
Over the last trailing twelve months MREO reported a non-GAAP Earnings per Share(EPS) of -0.26. The EPS increased by 36.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.77% | ||
| ROE | -89.46% | ||
| Debt/Equity | 0 |
MREO Forecast & Estimates
14 analysts have analysed MREO and the average price target is 2.12 USD. This implies a price increase of 297.93% is expected in the next year compared to the current price of 0.534.
MREO Ownership
MREO Latest News, Press Relases and Analysis
About MREO
Company Profile
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
Company Info
MEREO BIOPHARMA GROUP PL-ADR
One Cavendish Place, Fourth Floor
London W1G0QF GB
CEO: Denise Scots-Knight
Employees: 36
Phone: 443330237300
MEREO BIOPHARMA GROUP PL-ADR / MREO FAQ
What does MEREO BIOPHARMA GROUP PL-ADR do?
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
Can you provide the latest stock price for MEREO BIOPHARMA GROUP PL-ADR?
The current stock price of MREO is 0.534 USD. The price increased by 0.34% in the last trading session.
What is the dividend status of MEREO BIOPHARMA GROUP PL-ADR?
MREO does not pay a dividend.
How is the ChartMill rating for MEREO BIOPHARMA GROUP PL-ADR?
MREO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?
14 analysts have analysed MREO and the average price target is 2.12 USD. This implies a price increase of 297.93% is expected in the next year compared to the current price of 0.534.
What is the Price/Earnings (PE) ratio of MEREO BIOPHARMA GROUP PL-ADR (MREO)?
MEREO BIOPHARMA GROUP PL-ADR (MREO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.26).
What is the market capitalization of MREO stock?
MEREO BIOPHARMA GROUP PL-ADR (MREO) has a market capitalization of 84.98M USD. This makes MREO a Micro Cap stock.